TNF Pharmaceuticals Secures $7M in Private Placement
TNF Pharmaceuticals has closed a $7 million private placement financing of convertible preferred stock with its largest strategic stockholder and other existing stockholders. This financing, priced at a 44% premium to market, will support the company's development of light-based computing accelerator technology for blockchain. The company also issued Series H and I Convertible Preferred Stock and amended terms for Series F and F-1, extending maturity dates and removing amortization payments. TNF Pharmaceuticals focuses on innovative technologies and pharmaceutical candidates, with a current market cap of $6.73M.
TNF Pharmaceuticals ( (TNFA) ) just unveiled an update.
On September 4, 2025, TNF Pharmaceuticals announced the closing of a $7 million private placement financing of convertible preferred stock with its largest strategic stockholder and other existing stockholders. This financing, priced at a 44% premium to market, aims to support the company’s development milestones for its newly licensed light-based computing accelerator technology for blockchain. The company also completed transactions involving the issuance of Series H and Series I Convertible Preferred Stock and amended the terms of its Series F and Series F-1 Convertible Preferred Stock, extending their maturity dates and removing amortization payments.
More about TNF Pharmaceuticals
TNF Pharmaceuticals operates in the pharmaceutical industry, focusing on the development of innovative technologies and pharmaceutical candidates. The company is involved in the advancement of isomyosamine and Supera-CBD, and is exploring strategic opportunities to enhance shareholder value.
Average Trading Volume: 598,039
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.73M
